Skip to content
Oncology Research Hub

San Antonio, Texas

Cancer clinical trials in San Antonio, TX

195 cancer studies are recruiting participants at sites in San Antonio as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

San Antonio at a glance

  • 195 studies are recruiting at a site in San Antonio.
  • By phase: Phase 1 (68), Phase 1/2 (48), Phase 2 (19), Phase 2/3 (2), Phase 3 (37), No phase (7), Observational (14). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (156), university, hospital or other (33), government (6).
  • By research area: Breast Cancer (78), Lung Cancer (51), Lymphoma (33), Prostate Cancer (17), Pancreatic Cancer (11), Melanoma (5).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in San Antonio

Basic details from each study's public record (the 30 most recently updated of 195). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EMD Serono Research & Development Institute, Inc.
    Study site
    NEXT Oncology - PARENT
    Registry record
    NCT07360314 · updated
  2. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    START San Antonio (STSA)
    Registry record
    NCT07488676 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Texas Health Science Center at San Antonio
    Registry record
    NCT06058377 · updated
  4. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study site
    UT Health San Antonio's Mays Cancer Center
    Registry record
    NCT06270706 · updated
  5. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study sites
    START San Antonio, LLC · University of Texas Health Science Center San Antonio
    Registry record
    NCT06638307 · updated
  6. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    South Texas Accelerated Research Therapeutics (START), LLC
    Registry record
    NCT06827236 · updated
  7. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - San Antonio ( Site 8001)
    Registry record
    NCT06841354 · updated
  8. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - San Antonio ( Site 8004)
    Registry record
    NCT06966700 · updated
  9. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study sites
    NEXT Texas LLC - San Antonio · START San Antonio, LLC
    Registry record
    NCT07503808 · updated
  10. Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Immunomic Therapeutics, Inc.
    Study site
    START San Antonio
    Registry record
    NCT07652242 · updated
  11. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mays Cancer Center ( Site 0122)
    Registry record
    NCT06393374 · updated
  12. A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    South Texas Accelerated Research Therapeutics (START) San Antonio
    Registry record
    NCT07029399 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.

Lung cancer studies recruiting in San Antonio

  1. A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Tyligand Pharmaceuticals (Suzhou) Limited
    Study site
    NEXT Oncology
    Registry record
    NCT06385925 · updated
  2. A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    START San Antonio, LLC
    Registry record
    NCT07903415 · updated
  3. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    NEXT Oncology
    Registry record
    NCT03460977 · updated
  4. A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    START | San Antonio
    Registry record
    NCT06914128 · updated
  5. Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    START- San Antonio
    Registry record
    NCT07080242 · updated
  6. Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

    • No phase
    • Ages 50 to 80
    • All sexes
    Sponsor
    bioAffinity Technologies Inc.
    Study sites
    Audie Murphy VA Medical Center · Brooke Army Medical Center
    Registry record
    NCT07168993 · updated
  7. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    NEXT Oncology
    Registry record
    NCT07458347 · updated
  8. Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Texas Oncology - San Antonio
    Registry record
    NCT07680790 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.

Lymphoma studies recruiting in San Antonio

  1. Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    Cancer Therapy and Research Center at The UT Health Science Center at San Antonio
    Registry record
    NCT05676450 · updated
  2. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Methodist Children's Hospital
    Registry record
    NCT06173518 · updated
  3. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - San Antonio ( Site 8009)
    Registry record
    NCT06890884 · updated
  4. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas · University of Texas Health Science Center at San Antonio
    Registry record
    NCT04546399 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas · University of Texas Health Science Center at San Antonio
    Registry record
    NCT05675410 · updated
  6. TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

    • Phase 1/2
    • Up to age 1
    • All sexes
    Sponsor
    Tanja Andrea Gruber
    Study site
    University of Texas Health Science Center San Antonio
    Registry record
    NCT05848687 · updated
  7. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Texas Health Science Center at San Antonio
    Registry record
    NCT06337318 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in San Antonio, TX on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in San Antonio

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study sites
    Investigative Site US063 · Investigative Site US080
    Registry record
    NCT07522073 · updated
  2. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    START- San Antonio
    Registry record
    NCT07644559 · updated
  3. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immuneering Corporation
    Study site
    Texas Oncology - San Antonio
    Registry record
    NCT07562152 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.

Ask about studies near San Antonio

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call